, /PRNewswire/ -- DelveInsight's report includes a comprehensive understanding of current treatment practices, acne vulgaris emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ , the EU4 ( , , , and ) and the , and ]. Discover which therapies are expected to grab the major acne vulgaris market share @ Acne vulgaris, commonly known as acne, is a prevalent skin condition that affects millions of people worldwide, typically during adolescence but can persist into adulthood. It occurs when hair follicles become clogged with oil and dead skin cells, leading to the formation of pimples, blackheads, whiteheads, and in more severe cases, nodules and cysts.
The causes of acne vulgaris are multifactorial and include hormonal changes, genetics, excess oil production, bacteria (Propionibacterium acnes), inflammation, and certain medications. Hormonal fluctuations, such as those during puberty, menstruation, pregnancy, or hormonal disorders, can trigger or exacerbate acne by increasing oil production and causing skin cells to become sticky and clog pores. Symptoms of acne vulgaris vary from person to person and can range from mild to severe.
Common symptoms include the presence of blackheads (open comedones), whiteheads (closed comedones), papules (small, red bumps), pustules (pimples containing pus), nodules (large, painful lumps beneath the surface of the skin), and cysts (deep, pus-filled lesions). These l.
